🔍

PIIND - P I Industries

📊 NSE: PIIND 🏢 Pesticides / Agrochemicals - Indian 📅 Last Updated: 12/14/2025 10:49

📢 Recent Corporate Announcements

PI Industries Schedules One-on-One Meetings with Institutional Investors in March 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 05:36 PM

PI Industries Limited has announced a schedule for one-on-one interactions with institutional investors and broking houses in Mumbai. The company will meet with Motilal Oswal Financial Services on March 16, 2026, and the Narotam Sekhsaria Family Office on March 17, 2026. These meetings are part of the company's regular investor relations program under SEBI (LODR) Regulations. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions.

One-on-one meeting with Motilal Oswal Financial Services scheduled for March 16, 2026.
Interaction with Narotam Sekhsaria Family Office planned for March 17, 2026.
Both meetings are scheduled to take place in Mumbai.
Compliance with Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirmed that no unpublished price sensitive information will be disclosed.

💡 No immediate action is required as this is a routine regulatory disclosure. Investors should look for any post-meeting presentations or transcripts if the company chooses to release them for further insights.

PI Industries to Meet Motilal Oswal and Narotam Sekhsaria Family Office on March 16-17

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 05:33 PM

PI Industries has scheduled one-on-one interactions with two significant institutional entities in Mumbai. The company will meet with Motilal Oswal Financial Services on March 16, 2026, and Narotam Sekhsaria Family Office on March 17, 2026. These meetings are part of the company's regular investor relations outreach. The management has confirmed that no unpublished price sensitive information (UPSI) will be shared during these sessions.

One-on-one meeting with Motilal Oswal Financial Services scheduled for March 16, 2026.
Interaction with Narotam Sekhsaria Family Office set for March 17, 2026.
Both meetings are scheduled to take place in Mumbai as per the regulatory filing.
Disclosure made in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015.
Management stated that no unpublished price sensitive information will be discussed.

💡 This is a routine corporate event and requires no immediate action. Investors should look for any subsequent investor presentations or transcripts that may be uploaded to the exchanges following these meetings.

PI Industries to Meet India Capital Growth Fund on March 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Mar 2026, 03:40 PM

PI Industries Limited has scheduled a one-on-one interaction with India Capital Growth Fund on March 9, 2026. The meeting is set to take place in Mumbai as part of the company's regular investor engagement program. This disclosure is made in compliance with Regulation 30(6) of the SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction.

One-on-one meeting scheduled with India Capital Growth Fund in Mumbai.
Interaction date set for March 9, 2026, following the official intimation on March 4, 2026.
Compliance with SEBI (LODR) Regulations, 2015 for institutional investor interactions.
Confirmation that no unpublished price sensitive information (UPSI) will be disclosed during the call.

💡 No immediate action is required as this is a routine corporate disclosure for an investor meeting. Investors should continue to monitor the company's quarterly performance and any subsequent management commentary.

PI Industries to Meet Aditya Birla Sun Life Insurance on March 4, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 04:50 PM

PI Industries Limited has scheduled a one-on-one meeting with Aditya Birla Sun Life Insurance on March 4, 2026, in Mumbai. This interaction is part of the company's regular engagement with institutional investors under SEBI (LODR) Regulations. The company clarified that no unpublished price sensitive information will be disclosed during this session. Such meetings are typical for large-cap companies to maintain transparency and discuss general business outlooks with major institutional stakeholders.

One-on-one meeting scheduled with Aditya Birla Sun Life Insurance on March 4, 2026.
Interaction to be held in Mumbai under Regulation 30(6) of SEBI (LODR) Regulations.
Company confirms zero unpublished price sensitive information (UPSI) will be shared.
Disclosure filed on February 26, 2026, providing advance notice of the institutional interaction.

💡 This is a routine disclosure with no immediate impact on stock price; investors should monitor for any post-meeting transcripts or updated investor presentations if released.

PI Industries Schedules One-on-One Meeting with Equirus Securities on February 27

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Feb 2026, 06:13 PM

PI Industries Limited has announced a scheduled interaction with Equirus Securities on February 27, 2026. The meeting is a one-on-one session to be held in Mumbai as part of the company's regular investor outreach. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction. This disclosure is a routine compliance requirement under SEBI (LODR) Regulations.

One-on-one meeting with Equirus Securities scheduled for February 27, 2026
The interaction will take place in person in Mumbai
Compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015
No unpublished price sensitive information (UPSI) to be disclosed during the meeting

💡 No immediate action is required as this is a routine investor meeting; investors may look for any subsequent research notes from Equirus Securities.

PI Industries to Conduct Investor Meetings with Matthews Asia and Optimas Capital

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 05:46 PM

PI Industries Limited has announced a schedule for interactions with institutional investors in late February and early March 2026. The company will meet Matthews Asia from San Francisco on February 27, 2026, in a one-on-one format in Mumbai. Additionally, a virtual one-on-one meeting is scheduled with Optimas Capital, SG, on March 04, 2026. These interactions are conducted under SEBI (LODR) Regulations, and the company has stated that no unpublished price sensitive information will be shared.

One-on-one meeting with Matthews Asia (San Francisco) on February 27, 2026, in Mumbai.
Virtual one-on-one interaction with Optimas Capital (SG) scheduled for March 04, 2026.
Disclosure made under Regulation 30(6) of SEBI (LODR) Regulations, 2015.
Company explicitly stated that no unpublished price sensitive information (UPSI) will be shared.

💡 This is a routine regulatory filing; investors should monitor for any subsequent investor presentations that may provide deeper insights into the company's growth strategy.

PI Industries Schedules Investor Meetings with Axis Mutual Fund and Others on Feb 23

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Feb 2026, 05:03 PM

PI Industries Limited has announced a series of one-on-one interactions with institutional investors scheduled for February 23, 2026. The company will meet with Taksh Asset Management and Axis Mutual Fund in Mumbai, while a virtual session is planned with ITUS Capital. These meetings are part of the company's regular investor relations activities under SEBI regulations. The management has explicitly stated that no unpublished price sensitive information will be disclosed during these interactions.

Scheduled one-on-one meetings with three institutional investors on February 23, 2026.
Participants include Axis Mutual Fund, Taksh Asset Management, and ITUS Capital.
Meetings will be held through a mix of physical presence in Mumbai and virtual platforms.
Disclosure made in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015.

💡 This is a routine regulatory filing; no immediate action is necessary. Investors may look for subsequent investor presentations for updates on business strategy.

PI Industries to Meet Axis Mutual Fund and Other Institutional Investors on Feb 23

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Feb 2026, 05:01 PM

PI Industries Limited has scheduled a series of one-on-one meetings with institutional investors on February 23, 2026. The company will be interacting with Taksh Asset Management, ITUS Capital, and Axis Mutual Fund. These meetings are part of the company's regular investor relations program and will be conducted both in-person in Mumbai and virtually. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions.

Three separate one-on-one meetings scheduled for February 23, 2026.
Participating institutions include Axis Mutual Fund, ITUS Capital, and Taksh Asset Management.
Meetings will be held in Mumbai (physical) and via virtual platforms.
Compliance disclosure filed under Regulation 30(6) of SEBI (LODR) Regulations, 2015.

💡 This is a routine disclosure; investors should monitor the exchange for any investor presentations or transcripts that may be released following these meetings for insights into the company's outlook.

PI Industries to Meet Taksh Asset Management, ITUS Capital, and Axis Mutual Fund on Feb 23

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Feb 2026, 04:59 PM

PI Industries Limited has scheduled three separate one-on-one meetings with institutional investors on February 23, 2026. The company will interact with Taksh Asset Management and Axis Mutual Fund in person in Mumbai, while the meeting with ITUS Capital will be conducted virtually. These interactions are part of the company's regular investor relations program under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these sessions.

Scheduled one-on-one meetings with three institutional investors on February 23, 2026
Participants include Taksh Asset Management, ITUS Capital, and Axis Mutual Fund
Meetings will be conducted through both physical presence in Mumbai and virtual modes
Company confirmed that no unpublished price sensitive information will be disclosed

💡 This is a routine regulatory disclosure regarding investor engagement. No immediate action is required, but investors may look for any subsequent corporate presentations released on the exchanges.

PI Industries Releases Audio Recording of Q3 & 9M FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 13 Feb 2026, 12:17 PM

PI Industries has officially released the audio recording of its earnings conference call held on February 13, 2026. The call focused on the company's standalone and consolidated financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI Listing Obligations and Disclosure Requirements. Investors can access the recording on the company's website to hear management's detailed commentary on business operations and future outlook.

Audio recording of the Q3 FY26 earnings call is now available on the company's investor relations portal.
The call addressed financial results for the quarter and nine-month period ended December 31, 2025.
Disclosure made in compliance with Regulation 30 and 46 of SEBI (LODR) Regulations, 2015.
The recording provides direct access to management's responses to analyst and institutional investor queries.

💡 Investors should listen to the recording to understand management's guidance on the CSM business and domestic agrochemical demand. This is a routine update and does not contain new financial data beyond what was already reported in the results.

PI Industries Q3 FY26: Revenue Drops 28% YoY Amid Export Phasing; Pharma Grows 50% in 9M

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 10:27 PM

PI Industries reported a weak Q3 FY26 with consolidated revenue declining 28% YoY to ₹13,757 million, primarily driven by a 32% drop in Agchem exports due to customer delivery phasing. EBITDA margins contracted by 495 bps to 22%, although gross margins improved significantly by 631 bps to 59% due to a favorable product mix. The Pharma segment remains a bright spot, posting 50% YoY growth for 9M FY26. The company maintains a strong, debt-free balance sheet with a cash surplus of ₹35,066 million and declared an interim dividend of ₹5.00 per share.

Q3 FY26 Revenue fell 28% YoY to ₹13,757 Mn, while EBITDA declined 41% to ₹3,027 Mn.
Agchem Exports volume decreased 29% in Q3, impacted by delivery schedules and high base effects.
Pharma vertical revenue grew 50% YoY in 9M FY26 to ₹1,957 Mn, now contributing ~5% of exports.
Net Profit of ₹3,113 Mn includes an exceptional writeback of ₹1,260 Mn in contingent consideration.
9M FY26 Capex stood at ₹7,225 Mn, focusing on manufacturing and R&D infrastructure.

💡 Investors should watch for a volume recovery in Q4 as management indicates the Q3 decline was largely due to timing and delivery phasing. The rapid growth in the Pharma and Biologicals segments offers long-term diversification, but near-term stock performance may be pressured by the core Agchem slowdown.

PI Industries Declares Rs 5 Interim Dividend; Sets Feb 23, 2026 as Record Date

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 Feb 2026, 09:19 PM

PI Industries has declared an interim dividend of Rs 5 per equity share (500% of face value) for the financial year 2025-26. The company has fixed February 23, 2026, as the record date to determine eligible shareholders for this payout. Investors are required to submit tax-related documents by February 21, 2026, to ensure appropriate TDS rates are applied. Notably, the company will now process all dividend payments exclusively through electronic modes as per SEBI regulations.

Interim dividend of Rs 5 per equity share of face value Re 1 declared for FY 2025-26
Record date for determining shareholder eligibility is fixed as February 23, 2026
Standard TDS of 10% for resident shareholders with PAN; 20% for those without valid PAN/Aadhaar link
TDS exemption available for resident individuals if total dividend for FY 2025-26 does not exceed Rs 10,000
Deadline for submission of tax exemption forms (15G/15H) and other documents is February 21, 2026

💡 Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA to receive the dividend electronically. Eligible investors should submit Form 15G/15H by February 21 to avoid higher tax deductions.

PI Industries Declares ₹5 Interim Dividend; Q3 Consolidated Revenue Falls 27.6% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 07:04 PM

PI Industries reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹13,757 million from ₹19,008 million in the previous year. Consolidated net profit also decreased to ₹3,113 million compared to ₹3,727 million YoY, despite a net exceptional gain of ₹1,051 million. To reward shareholders, the board declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. The company also recognized a ₹206 million exceptional charge on a standalone basis due to the implementation of New Labour Codes.

Consolidated revenue from operations declined 27.6% YoY to ₹13,757 million.
Consolidated PAT for the quarter stood at ₹3,113 million, down 16.5% from ₹3,727 million YoY.
Interim dividend of ₹5 per equity share (500%) declared with a record date of Feb 23, 2026.
Exceptional gain of ₹1,051 million reported in consolidated results for the quarter.
Basic EPS decreased to ₹20.52 from ₹24.55 in the corresponding quarter of the previous year.

💡 Investors should exercise caution as the sharp decline in top-line growth and margins indicates headwinds in the agrochemical sector. While the ₹5 dividend provides some immediate yield, the focus should remain on management's outlook for demand recovery.

PI Industries Declares ₹5 Interim Dividend Amidst Sharp Decline in Q3 Revenue

🔴 NEGATIVE ⭐ 8/10

DIVIDEND 📅 12 Feb 2026, 07:03 PM

PI Industries has declared an interim dividend of ₹5 per equity share (500% of face value) for FY26, with the record date set for February 23, 2026. The company's consolidated revenue for Q3 FY26 saw a significant decline to ₹13,757 million from ₹19,008 million in the same period last year. Consolidated net profit stood at ₹3,113 million, which was bolstered by a one-time exceptional gain of ₹1,051 million. Standalone performance was notably weaker, with revenue falling nearly 29% YoY to ₹12,696 million.

Interim dividend of ₹5 per share declared with a record date of February 23, 2026.
Consolidated revenue from operations fell 27.6% YoY to ₹13,757 million in Q3 FY26.
Consolidated PAT decreased to ₹3,113 million from ₹3,727 million in the previous year's quarter.
Standalone PAT dropped significantly to ₹2,816 million compared to ₹4,238 million YoY.
An exceptional gain of ₹1,051 million was recorded at the consolidated level, offsetting operational weakness.

💡 The sharp contraction in both revenue and standalone profits indicates significant operational headwinds in the agrochemical segment. Investors should focus on the sustainability of margins and management's outlook on demand recovery before making new entries.

PI Industries Q3 Net Profit Falls 16.5% to ₹311 Cr; Declares ₹5 Interim Dividend

🔴 NEGATIVE ⭐ 9/10

EARNINGS 📅 12 Feb 2026, 07:01 PM

PI Industries reported a weak set of numbers for Q3 FY26, with consolidated revenue from operations declining 27.6% YoY to ₹13,757 million. Consolidated net profit for the quarter fell 16.5% to ₹3,113 million, even after accounting for a net exceptional gain of ₹1,051 million. The company declared an interim dividend of ₹5 per share (500% of face value) with a record date of February 23, 2026. Standalone performance mirrored the consolidated trend, with revenue dropping nearly 29% YoY, reflecting significant headwinds in the agrochemical sector.

Consolidated Revenue from operations dropped 27.6% YoY to ₹13,757 million from ₹19,008 million in the previous year.
Consolidated Net Profit decreased by 16.5% YoY to ₹3,113 million, supported by an exceptional gain of ₹1,051 million.
Declared an interim dividend of ₹5 per equity share for FY 2025-26, payable by March 13, 2026.
Standalone results included an exceptional loss of ₹206 million due to the implementation of New Labour Codes.
The company confirmed that the entire ₹20,000 million raised through QIP in 2020 has now been fully utilized.

💡 The significant decline in both top-line and bottom-line performance suggests a challenging environment for the company's core agrochemical business. Investors should exercise caution and wait for management commentary on demand recovery and the nature of the consolidated exceptional gain before making new entries.

View All PIIND Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 5% YoY to INR 6,191 Cr during the first nine months of fiscal 2025. The CSM segment remains the primary driver, while the domestic agrochemical segment de-grew due to inventory de-stocking and pricing pressure from excess global supply.

Geographic Revenue Split

The domestic business constitutes approximately 24% of total revenues, with the remaining 76% primarily derived from exports through the CSM (Custom Synthesis and Manufacturing) business to global innovators in markets like Japan, the US, and Brazil.

Profitability Margins

Operating margins have shown resilience, improving to 27.8% in 9M FY25 from 26.7% in 9M FY24. This was driven by a favorable product mix and higher gross margins, despite higher overheads from scaling the pharma and export businesses.

EBITDA Margin

EBITDA margin stood at 27.8% for 9M FY25, reflecting a 110 bps improvement YoY. Core profitability is supported by the niche CSM model for IP-backed early-stage molecules where margins are generally stable and healthy.

Capital Expenditure

The company maintains a planned capex of approximately INR 650 Cr per annum, supported by strong annual net cash accruals (NCA) of INR 1,800 Cr to 2,000 Cr. Historical QIP proceeds of INR 2,000 Cr also support inorganic expansion.

Credit Rating & Borrowing

The company holds a 'CRISIL AA+/Stable' long-term rating and 'CRISIL A1+' short-term rating. Borrowing costs are minimized by a very low debt-to-EBITDA ratio of 0.23x and an interest coverage ratio of 80x.

⚙️ Operational Drivers

Raw Materials

Specific raw materials include agrochemical intermediates and early-stage molecules for CSM; however, specific chemical names and their exact % of total cost are not disclosed in the provided documents.

Import Sources

A significant portion of raw material supply and pricing is influenced by the 'supply deluge from China,' indicating heavy reliance on Chinese imports for the agrochemical sector.

Capacity Expansion

The company is currently in an investment phase, building capabilities in the Pharma CDMO and Biologicals segments. It plans to launch 5 new products in the domestic market annually to expand its footprint.

Raw Material Costs

Gross margins improved by 103 bps recently despite RM price inflation, suggesting a strong ability to pass on costs or optimize product mix. Raw material costs are highly sensitive to Chinese supply dynamics.

Manufacturing Efficiency

Efficiency is driven by maturing new product launches and a focused approach to horticulture through the 'JIVAGRO' brand, alongside a low Lost Time Injury Frequency Rate (LTIFR) of 0.09.

Logistics & Distribution

The company extends credit of 90-120 days to dealers and distributors, which is a standard requirement in the working-capital-intensive domestic agrochemical industry.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth will be achieved through a USD 1.4 billion (INR 13,000 Cr) order book, the commercialization of new molecules every year, and the ramp-up of newly acquired pharma and biological entities. The company is also expanding its 'go-to-market' strategy in the US and Brazil for its biologicals business.

Products & Services

CSM of early-stage molecules, branded agrochemical formulations, peptides, biologicals, and Pharma CDMO services.

Brand Portfolio

JIVAGRO

New Products/Services

The company plans to launch 5 new products in the domestic market. New product development is also focused on label expansions for peptides in the US and Brazil.

Market Expansion

Targeting expansion in the US and Brazil for the biologicals business and increasing the share of own branded formulations in the domestic market.

Strategic Alliances

Strong tie-ups with global innovators for CSM and in-licensing business for the domestic market.

🌍 External Factors

Industry Trends

The industry is shifting toward biologicals and specialized CDMO services. PI is positioning itself by acquiring biological entities and filing for peptide registrations to move beyond traditional agrochemicals.

Competitive Landscape

Competitors include global and domestic agrochemical players, though PI's CSM focus differentiates it from pure-play generic manufacturers.

Competitive Moat

The moat is built on long-term relationships with global innovators and a USD 1.4 billion order book, which provides high revenue visibility and high switching costs for clients due to the IP-backed nature of the products.

Macro Economic Sensitivity

The domestic business is highly sensitive to the vagaries of the monsoon and levels of farm income, which dictate demand for agrochemicals.

Consumer Behavior

Increasing demand for sustainable and biological crop protection products is driving the company's investment in peptides and renewable energy.

Geopolitical Risks

Susceptibility to separate registration processes in different countries for crop protection products and trade dynamics with China.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent registration processes for agrochemicals in various global jurisdictions and compliance with GRI standards and UN SDGs.

Environmental Compliance

The company has integrated sustainability into its core strategy with a dedicated Sustainability Council and aims to increase women in leadership by 25% by 2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timing of recovery from industry-wide inventory de-stocking, which impacted H1 FY25 revenues. Potential impact could be a moderation in growth to below 10% if de-stocking persists.

Geographic Concentration Risk

76% of revenue is concentrated in export markets, making the company sensitive to global regulatory changes and international trade barriers.

Third Party Dependencies

High dependency on global innovators for CSM contracts and Chinese suppliers for raw material intermediates.

Technology Obsolescence Risk

The company mitigates technology risk by investing in early-stage molecules and biologicals (peptides) to stay ahead of traditional chemical pesticide obsolescence.

Credit & Counterparty Risk

Receivables are managed through a 90-120 day credit cycle; however, the company's strong cash position of INR 4,158 Cr provides a significant buffer against counterparty defaults.